Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
ArcheHealth Appoints Advisory Board to Guide Strategy and Product Development
ArcheHealth, which is positioned to be the healthcare operational intelligence leader, announced that it has appointed an advisory board of notable health IT veterans, clinical experts, and entrepreneurs to guide strategy and product development as the company launches its AI-powered healthcare cost reduction solution.
Kyle Kinzie Named President and Partner at Slone Partners
Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced that renowned senior executive and organizational leader Kyle Kinzie has joined the company as President & Partner, Hospitals & Healthcare Delivery Solutions.
ViCentra to Launch Smartphone-Based Diabetes Therapy in 2026
ViCentra, maker of the Kaleido insulin patch pump, announced that following the CE Mark approval of Diabeloop’s DBLG2 algorithm under the EU Medical Device Regulation (MDR), its next-generation hybrid closed loop system is set to launch in Germany and the Netherlands in early 2026.
Dr. Chadwick Richard Offers Hybrid Choice Concierge Program
Concierge Choice Physicians (CCP), the nation’s leading full-service concierge medical service provider, announces today that Medical Clinic of Houston (MCH) internal medicine physician Chadwick Richard, M.D., is the latest physician to now offer CCP’s Hybrid Choice, a unique healthcare program that gives patients the option of a more comprehensive, convenient and personal form of medical care.
Fosun Pharma’s Xh-S004 Drug Earns $645 Million Overseas Licensing
On August 11, Fosun Pharma announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc. to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. Fosun Pharma will retain the rights to develop, manufacture, and commercialize XH-S004 in Chinese Mainland, Hong Kong SAR and Macau SAR.
To share your insights, please write to us at sudipto@intentamplify.com
